Bringing the fundamentals into focus…
Back to Lineage Cell Therapeutics, Inc.
How Lineage Cell Therapeutics, Inc. stacks up
LCTX · against 313 other Healthcare companies of similar size
Profitability
10/ 100
Near the bottom of its peers.
Ranked #266 of 314 · scores higher than 14% of peers
Bars: peers in each 10-point band of the profitability score38 peers with a profitability score of 10–19, including LCTX · Click a bar to see the companies
Why profitability scores 10?
Weighted metrics compared with all Healthcare companies.Mainly because of its return on invested capital, operating margin and return on assets, which are weaker than most Healthcare peers.
- a lower return on invested capital: weaker than 92% of peers. Return on invested capital: -90.0% vs peer median 4.7%
- a thinner operating margin: weaker than 90% of peers. Operating margin: -205.2% vs peer median 7.1%
- a lower return on assets: weaker than 86% of peers. Return on assets: -30.4% vs peer median 1.7%
Metric by metric
Position: dot = LCTX, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | LCTX | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Return on invested capitalHigher is better · 275 reported | -90.0% | -0.8% | 9% | 33% | |
| Operating marginHigher is better · 293 reported | -205.2% | 2.0% | 15% | 33% | |
| Return on assetsHigher is better · 315 reported | -30.4% | -0.5% | 18% | 33% | |
| Return on equityHigher is better · 295 reported | -60.1% | -0.8% | 13% | Context only | |
| Gross marginHigher is better · 330 reported | -57.4% | 39.0% | 3% | Context only |
Ranking by profitability score
Top 5 and the companies ranked around LCTX| Rank | Company | Market cap | Profitability | Overall |
|---|---|---|---|---|
| 1 | 433M USD | 99 | 81 | |
| 2 | 261M USD | 98 | 97 | |
| 3 | 1.4B HKD (≈$181M) | 97 | 61 | |
| 3 | 356M AUD (≈$235M) | 97 | 81 | |
| 5 | 592M ILS (≈$160M) | 96 | 84 | |
| 262 | 474M USD | 11 | 25 | |
| 266 | 7.2B TWD (≈$224M) | 10 | 41 | |
| 266 | 377M USD | 10 | 29 | |
| 266 | 334M USD | 10 | 36 | |
| 266 | 255M USD | 10 | 36 | |
| 266 | 302M USD | 10 | 42 | |
| 266 | 504M USD | 10 | 24 | |
| 272 | 395M USD | 9 | 30 | |
| 272 | 399M USD | 9 | 32 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score